Navigation Links
Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2010 Financial Results
Date:6/2/2010

 In addition, we are the world's leading supplier of recombinant Protein A, the sales of which partially fund the advancement of our development pipeline while supporting our financial stability.  Repligen's corporate headquarters are located at 41 Seyon Street, Building #1, Suite 100, Waltham, MA 02453.  Additional information may be requested from www.repligen.com.

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding current or future financial performance and position, management's strategy, plans and objectives for future operations, plans and objectives for product development, plans and objectives for present and future clinical trials and results of such trials, plans and objectives for regulatory approval, litigation, intellectual property, product development, manufacturing plans and performance such as the anticipated growth in the monoclonal antibody market and our other target markets and projected growth in product sales, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: the success of current and future collaborative relationshi
'/>"/>

SOURCE Repligen Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
2. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
3. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
4. Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
5. Repligen Receives Research Grants to Support Friedreichs Ataxia Development Program
6. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
7. Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT
8. Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST
9. Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results
10. Repligen to Present at the BIO CEO & Investor Conference Monday, February 9th, 11:30 a.m. EST
11. Repligen Reports Third Quarter Fiscal Year 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... The participants committed to not only creating unique ... time adjusting, tweaking and testing virtual models and 3D ... judging. , “I enjoyed being involved as a judge,” ... entries showed a commendable range exploring the technical capabilities ... medium and the creativity of the contestants.” , Array ...
(Date:10/1/2014)... 30, 2014 New applications of structures ... have evolved in nature over millennia are featured in ... for applications in biophotonics in the October issue ... journal is published by SPIE, the international society for ... of the peer-reviewed articles are accessible via open access. ...
(Date:10/1/2014)... TeselaGen Biotechnology has received ... expand their bioCAD/CAM software suite, which uses synthetic ... Small Business Innovation Research Phase II grant will be ... license from the Lawrence Berkeley National Laboratory. j5 was ... LBNL laboratory that develops alternative fuel technologies for the ...
(Date:10/1/2014)... 2014 Industry leaders from ... engage around the theme, ,Commercial Opportunities in the Era ... Elsevier , a world-leading provider of ... host a gathering of some of the industry,s most ... healthcare today and in the future. The ...
Breaking Biology Technology:Array Architects Challenges Staff to Create with 3D Printer 2Biomimetic and bioinspired materials enable new healthcare options, reports Journal of Biomedical Optics 2Biomimetic and bioinspired materials enable new healthcare options, reports Journal of Biomedical Optics 3TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 3
... NicOx S.A.,(NYSE Euronext Paris: COX) today announced ... the commercial manufacture and supply of naproxcinod ... is NicOx, lead,investigational product and the first ... of,anti-inflammatory agents, which recently achieved positive results ...
... Sinovac Biotech Ltd. (NYSE Alternext,US: SVA), a leading provider of ... Fengtai District in the City of Beijing suspended,the use of ... of the death of a minor in the Fengtai District ... vaccine two days prior. , ...
... market research firm SharpBrains, will lead a webinar discussing the Top ... providers. , ... San Francisco, CA (PRWEB) December 2, ... World Economic Forum,s Council on the Challenges of Gerontology, will lead ...
Cached Biology Technology:NicOx Signs Agreement With DSM for the Commercial Manufacture of Naproxcinod Drug Substance 2NicOx Signs Agreement With DSM for the Commercial Manufacture of Naproxcinod Drug Substance 3NicOx Signs Agreement With DSM for the Commercial Manufacture of Naproxcinod Drug Substance 4Sinovac Releases Statement on Healive Vaccine Suspension 2Top 10 Cognitive Fitness Events of 2008 to be Unveiled at SharpBrains' Webinar 2Top 10 Cognitive Fitness Events of 2008 to be Unveiled at SharpBrains' Webinar 3
(Date:10/1/2014)... microbes that thrive in the deserts, rainforests, prairies and ... beneath New York City,s Central Park, according to a ... the University of Colorado Boulder. , The research ... Park,s 843 acres and discovered a stunning diversity of ... before. , Only 8.5 percent to 16.2 percent ...
(Date:9/30/2014)... by the Ocean Health Index rates the Earth,s ... health. In addition, for the first time, the ... regions beyond national jurisdiction (high-seas areas) all ... biodiversity and providing sustainable food sources. , In ... partnership led by scientists from UC Santa Barbara,s ...
(Date:9/30/2014)... scientists and engineers, led by Clemson University associate ... million grant from the U.S. Department of Energy,s ... a direct positive impact on South Carolina in ... radioactive contaminants. , "Understanding the scientific and engineering ... aspects of nuclear technologies is imperative if South ...
Breaking Biology News(10 mins):Microbes in Central Park soil: If they can make it there, they can make it anywhere 2Microbes in Central Park soil: If they can make it there, they can make it anywhere 3Rating the planet's oceans 2Rating the planet's oceans 3Researchers get $5.25 million to advance nuclear technologies in South Carolina 2
... (March 5, 2013) Researchers have discovered that deleting a ... on a high fat diet, a finding they believe may ... induces obesity these mice don,t get fat," said Prof. James ... research for Obstetrics and Gynecology at the University of Colorado ...
... Center scientists report the first successful blocking of tumor development in ... my knowledge, this is the first time that a mouse model ... which the formation of the tumor from beginning to end can ... of the tumor," said Dr. Luis Parada , chair of ...
... 2013) Researchers at the University of Minnesota,s ... cellular reprogramming to generate stem cells capable of ... Muscular Dystrophy (DMD). The research, which ... pluripotent stem cell technology and genetic correction to ...
Cached Biology News:Researchers discover gene that causes obesity in mice 2UT Southwestern scientists make mouse model of human cancer, demonstrate cure 2UT Southwestern scientists make mouse model of human cancer, demonstrate cure 3U of M researchers utilize genetically corrected stem cells to spark muscle regeneration 2U of M researchers utilize genetically corrected stem cells to spark muscle regeneration 3
Mouse monoclonal [7B9] to beta II Tubulin ( Abpromise for all tested applications). Antigen: Synthetic peptide, CEEEEGEDEA found at the c-terminus of beta II tubulin. Entrez GeneID: 10383 ...
...
... used in conjuction with Annexin V-FITC to ... stages of apoptosis (Annexin V positive, PI ... stages of apoptosis or already dead (Annexin ... in the orange range of the spectrum ...
... were cultured in RPMI 1640 with 2 mM ... growth. In order to keep the antigens ... acetone-methanol. The cells are arrayed on a ... wells surface specifically treated to enhance cellular attachment ...
Biology Products: